Report Detail
Global Hemoglobinopathies Drugs Market Insights, Forecast to 2025
- RnM2850118 |
- 04 February, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
The global Hemoglobinopathies Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hemoglobinopathies Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Hemoglobinopathies Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hemoglobinopathies Drugs in these regions.
This research report categorizes the global Hemoglobinopathies Drugs market by top players/brands, region, type and end user. This report also studies the global Hemoglobinopathies Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Gamida Cell
Alnylam Pharmaceuticals
Biogen Idec
Sangamo BioSciences Inc.
Genetix Pharmaceuticals/Bluebird Bio
Global Blood Therapeutics Inc.
Pfizer Inc.
Mast Therapeutics
Emmaus Life Sciences, Inc.
Prolong Pharmaceuticals
Celgene Corporation
HemaQuest Pharmaceuticals
Market size by Product
Thalassemia Therapy
Sickle Cell Disease(SCD) Therapy
Other Therapy
Market size by End User
Alpha Thalassemia
Beta thalassemia
Sickle Cell Disease
Hb Variants Diseases
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Hemoglobinopathies Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hemoglobinopathies Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hemoglobinopathies Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hemoglobinopathies Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Hemoglobinopathies Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hemoglobinopathies Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Hemoglobinopathies Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Hemoglobinopathies Drugs Market Size Growth Rate by Product
- 1.4.2 Thalassemia Therapy
- 1.4.3 Sickle Cell Disease(SCD) Therapy
- 1.4.4 Other Therapy
- 1.5 Market by End User
- 1.5.1 Global Hemoglobinopathies Drugs Market Size Growth Rate by End User
- 1.5.2 Alpha Thalassemia
- 1.5.3 Beta thalassemia
- 1.5.4 Sickle Cell Disease
- 1.5.5 Hb Variants Diseases
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Hemoglobinopathies Drugs Market Size
- 2.1.1 Global Hemoglobinopathies Drugs Revenue 2014-2025
- 2.1.2 Global Hemoglobinopathies Drugs Sales 2014-2025
- 2.2 Hemoglobinopathies Drugs Growth Rate by Regions
- 2.2.1 Global Hemoglobinopathies Drugs Sales by Regions
- 2.2.2 Global Hemoglobinopathies Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Hemoglobinopathies Drugs Sales by Manufacturers
- 3.1.1 Hemoglobinopathies Drugs Sales by Manufacturers
- 3.1.2 Hemoglobinopathies Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Hemoglobinopathies Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Hemoglobinopathies Drugs Revenue by Manufacturers
- 3.2.1 Hemoglobinopathies Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Hemoglobinopathies Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Hemoglobinopathies Drugs Price by Manufacturers
- 3.4 Hemoglobinopathies Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Hemoglobinopathies Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Hemoglobinopathies Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Hemoglobinopathies Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Hemoglobinopathies Drugs Sales by Product
- 4.2 Global Hemoglobinopathies Drugs Revenue by Product
- 4.3 Hemoglobinopathies Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Hemoglobinopathies Drugs Breakdown Data by End User
6 North America
- 6.1 North America Hemoglobinopathies Drugs by Countries
- 6.1.1 North America Hemoglobinopathies Drugs Sales by Countries
- 6.1.2 North America Hemoglobinopathies Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Hemoglobinopathies Drugs by Product
- 6.3 North America Hemoglobinopathies Drugs by End User
7 Europe
- 7.1 Europe Hemoglobinopathies Drugs by Countries
- 7.1.1 Europe Hemoglobinopathies Drugs Sales by Countries
- 7.1.2 Europe Hemoglobinopathies Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Hemoglobinopathies Drugs by Product
- 7.3 Europe Hemoglobinopathies Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Hemoglobinopathies Drugs by Countries
- 8.1.1 Asia Pacific Hemoglobinopathies Drugs Sales by Countries
- 8.1.2 Asia Pacific Hemoglobinopathies Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Hemoglobinopathies Drugs by Product
- 8.3 Asia Pacific Hemoglobinopathies Drugs by End User
9 Central & South America
- 9.1 Central & South America Hemoglobinopathies Drugs by Countries
- 9.1.1 Central & South America Hemoglobinopathies Drugs Sales by Countries
- 9.1.2 Central & South America Hemoglobinopathies Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Hemoglobinopathies Drugs by Product
- 9.3 Central & South America Hemoglobinopathies Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Hemoglobinopathies Drugs by Countries
- 10.1.1 Middle East and Africa Hemoglobinopathies Drugs Sales by Countries
- 10.1.2 Middle East and Africa Hemoglobinopathies Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Hemoglobinopathies Drugs by Product
- 10.3 Middle East and Africa Hemoglobinopathies Drugs by End User
11 Company Profiles
- 11.1 Gamida Cell
- 11.1.1 Gamida Cell Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Gamida Cell Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Gamida Cell Hemoglobinopathies Drugs Products Offered
- 11.1.5 Gamida Cell Recent Development
- 11.2 Alnylam Pharmaceuticals
- 11.2.1 Alnylam Pharmaceuticals Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Products Offered
- 11.2.5 Alnylam Pharmaceuticals Recent Development
- 11.3 Biogen Idec
- 11.3.1 Biogen Idec Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Biogen Idec Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Biogen Idec Hemoglobinopathies Drugs Products Offered
- 11.3.5 Biogen Idec Recent Development
- 11.4 Sangamo BioSciences Inc.
- 11.4.1 Sangamo BioSciences Inc. Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Products Offered
- 11.4.5 Sangamo BioSciences Inc. Recent Development
- 11.5 Genetix Pharmaceuticals/Bluebird Bio
- 11.5.1 Genetix Pharmaceuticals/Bluebird Bio Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Products Offered
- 11.5.5 Genetix Pharmaceuticals/Bluebird Bio Recent Development
- 11.6 Global Blood Therapeutics Inc.
- 11.6.1 Global Blood Therapeutics Inc. Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Products Offered
- 11.6.5 Global Blood Therapeutics Inc. Recent Development
- 11.7 Pfizer Inc.
- 11.7.1 Pfizer Inc. Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Pfizer Inc. Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Pfizer Inc. Hemoglobinopathies Drugs Products Offered
- 11.7.5 Pfizer Inc. Recent Development
- 11.8 Mast Therapeutics
- 11.8.1 Mast Therapeutics Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Mast Therapeutics Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Mast Therapeutics Hemoglobinopathies Drugs Products Offered
- 11.8.5 Mast Therapeutics Recent Development
- 11.9 Emmaus Life Sciences, Inc.
- 11.9.1 Emmaus Life Sciences, Inc. Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Products Offered
- 11.9.5 Emmaus Life Sciences, Inc. Recent Development
- 11.10 Prolong Pharmaceuticals
- 11.10.1 Prolong Pharmaceuticals Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Prolong Pharmaceuticals Hemoglobinopathies Drugs Products Offered
- 11.10.5 Prolong Pharmaceuticals Recent Development
- 11.11 Celgene Corporation
- 11.12 HemaQuest Pharmaceuticals
12 Future Forecast
- 12.1 Hemoglobinopathies Drugs Market Forecast by Regions
- 12.1.1 Global Hemoglobinopathies Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Hemoglobinopathies Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Hemoglobinopathies Drugs Market Forecast by Product
- 12.2.1 Global Hemoglobinopathies Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Hemoglobinopathies Drugs Revenue Forecast by Product 2019-2025
- 12.3 Hemoglobinopathies Drugs Market Forecast by End User
- 12.4 North America Hemoglobinopathies Drugs Forecast
- 12.5 Europe Hemoglobinopathies Drugs Forecast
- 12.6 Asia Pacific Hemoglobinopathies Drugs Forecast
- 12.7 Central & South America Hemoglobinopathies Drugs Forecast
- 12.8 Middle East and Africa Hemoglobinopathies Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Hemoglobinopathies Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Hemoglobinopathies Drugs . Industry analysis & Market Report on Hemoglobinopathies Drugs is a syndicated market report, published as Global Hemoglobinopathies Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Hemoglobinopathies Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
